Skip to main content

Dr. Jennifer Pearlman

Welcome to Health Advisor, where contributors share their knowledge in fields ranging from fitness to psychology, pediatrics to aging. Follow us @Globe_Health.

The United Nations has declared the theme for this year's International Women's Day as one of "Inspiring Change" to celebrate the achievements of women while still focusing on the gender gaps that persist globally. Sadly, gender inequities remain pervasive across society and certainly throughout health care.

As a young medical student, I could never understand why our medical curriculum did not better differentiate human biology, physiology and pharmacology between the sexes. Often, women are contemplated as "mini-men."

Story continues below advertisement

By most measures it becomes apparent that medical progress has improved the lives and health status of women to a lesser extent than it has men. While women are outliving men by an average of 6.3 years, they enjoy only an additional 1.5 years of disability-free years of life. This paradox points to an emerging gender gap in medical advancement.

Indeed, with a "male-centric" focus, biomedical research has yielded meaningful improvements in the detection and management of diseases that affect men, such as heart disease, more so than those that disproportionately affect women, such as chronic pain, depression, autoimmune disease and breast cancer. And it is not only the research agenda that is male-focused, but so too the subjects.

There is a significant sex bias in drug trials with serious underrepresentation of females throughout biomedical studies, from basic research to human clinical trials. While the average chronic pain patient is a 55-year-old woman, the average chronic pain research subject is a male mouse.

Females are excluded from both animal and human clinical trials often due to concerns about the variability introduced by their hormonal cycles.

Simply, it is easier to study males.

And so it is that early stage clinical trials study predominantly male animals and young healthy men. As a result, novel medical therapies that progress through to late-stage clinical trials and ultimately to market may be less effective, less safe and less relevant for women. Sex differences in drug effects and metabolism have largely been overlooked. But they matter.

Variable pharmacodynamics, or drug metabolism, mean that there may be risk of drug toxicity or, conversely, a lack of therapeutic effect.

Story continues below advertisement

Illustrating this problem is the case of Ambien, a commonly prescribed sleep medication. Reports of excess sedation in women due to slower metabolism have prompted health regulators for the first time to recommend lower dosages of the drug in women.

The study of epigenetics or gene expression is revealing how a shared genetic substrate may be differentially expressed in men and women. Approximately 70 per cent of the human genome shows sex-biased expression contributing to the gender differences seen in biology, behaviour and susceptibilities.

Lifestyle factors and environmental exposures affect the health of women differently from men.

Heart disease is a case in point. The traditional risks, such as high cholesterol and blood pressure, are more specific to men. Diabetes, metabolic syndrome, smoking, hormonal status and stress increase risk to a greater extent in women than in men. Accounting for the differentiated expression of the genome between the sexes will be necessary to the development of gender-specific preventative health strategies.

So what will the winds of change and medical progress mean for women's health? Hopefully, a deeper understanding of the gender differences that exist from bench to bedside and the development of strategies to prevent, detect and treat disease accordingly.

Dr. Jennifer Pearlman is a physician focused on women's health and wellness, a staff physician at the Menopause Clinic at Mount Sinai Hospital in Toronto and medical director of PearlMDRejuvenation, a Women's health and wellness facility.

Story continues below advertisement

Report an error Editorial code of conduct
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter